CA3007426A1 - Monitoring treatment or progression of myeloma - Google Patents
Monitoring treatment or progression of myeloma Download PDFInfo
- Publication number
- CA3007426A1 CA3007426A1 CA3007426A CA3007426A CA3007426A1 CA 3007426 A1 CA3007426 A1 CA 3007426A1 CA 3007426 A CA3007426 A CA 3007426A CA 3007426 A CA3007426 A CA 3007426A CA 3007426 A1 CA3007426 A1 CA 3007426A1
- Authority
- CA
- Canada
- Prior art keywords
- individual
- kras
- cell
- nucleic acids
- multiple myeloma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015905013 | 2015-12-03 | ||
| AU2015905013A AU2015905013A0 (en) | 2015-12-03 | Monitoring treatment or progression of myeloma | |
| AU2016903019 | 2016-08-01 | ||
| AU2016903019A AU2016903019A0 (en) | 2016-08-01 | Monitoring treatment or progression of myeloma (2) | |
| PCT/AU2016/051191 WO2017091865A1 (en) | 2015-12-03 | 2016-12-02 | Monitoring treatment or progression of myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3007426A1 true CA3007426A1 (en) | 2017-06-08 |
Family
ID=58796005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3007426A Pending CA3007426A1 (en) | 2015-12-03 | 2016-12-02 | Monitoring treatment or progression of myeloma |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180282820A1 (https=) |
| EP (1) | EP3384050A4 (https=) |
| JP (2) | JP2018537128A (https=) |
| KR (1) | KR20180088690A (https=) |
| CN (1) | CN108603232A (https=) |
| AU (1) | AU2016363113A1 (https=) |
| CA (1) | CA3007426A1 (https=) |
| WO (1) | WO2017091865A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107881233A (zh) * | 2017-10-31 | 2018-04-06 | 天津协和华美医学诊断技术有限公司 | 一种检测骨髓瘤相关基因群的检测试剂盒 |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| RU2671980C2 (ru) | 2011-02-09 | 2018-11-08 | Натера, Инк. | Способы неинвазивного пренатального установления плоидности |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| US20180173846A1 (en) | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
| RU2760913C2 (ru) | 2016-04-15 | 2021-12-01 | Натера, Инк. | Способы выявления рака легкого |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| GB201618485D0 (en) | 2016-11-02 | 2016-12-14 | Ucl Business Plc | Method of detecting tumour recurrence |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| US11773434B2 (en) | 2017-06-20 | 2023-10-03 | The Medical College Of Wisconsin, Inc. | Assessing transplant complication risk with total cell-free DNA |
| WO2019075251A2 (en) * | 2017-10-12 | 2019-04-18 | Nantomics, Llc | CANCER SCORE FOR EVALUATION AND PREDICTION OF RESPONSE FROM BIOLOGICAL FLUIDS |
| US12084720B2 (en) | 2017-12-14 | 2024-09-10 | Natera, Inc. | Assessing graft suitability for transplantation |
| US12024738B2 (en) | 2018-04-14 | 2024-07-02 | Natera, Inc. | Methods for cancer detection and monitoring |
| EP3784805A1 (en) * | 2018-04-23 | 2021-03-03 | Inivata Limited | Method for predicting and monitoring response to an immune checkpoint inhibitor |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| WO2020031048A1 (en) | 2018-08-08 | 2020-02-13 | Inivata Ltd. | Method of sequencing using variable replicate multiplex pcr |
| CN113874525A (zh) * | 2018-10-29 | 2021-12-31 | 分子听诊器公司 | 使用无细胞信使rna的骨髓表征 |
| WO2020092646A1 (en) * | 2018-10-30 | 2020-05-07 | Molecular Stethoscope, Inc. | Cell-free rna library preparations |
| WO2020131955A1 (en) * | 2018-12-17 | 2020-06-25 | The Medical College Of Wisconsin, Inc. | Assessing risk with total cell-free dna |
| US11931674B2 (en) | 2019-04-04 | 2024-03-19 | Natera, Inc. | Materials and methods for processing blood samples |
| US20210087638A1 (en) * | 2019-09-23 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Next-generation sequencing assay for genomic characterization and minimal residual disease detection in the bone marrow, peripheral blood, and urine of multiple myeloma and smoldering myeloma patients |
| CN112760290A (zh) * | 2019-10-21 | 2021-05-07 | 郑州大学 | 携带突变的肿瘤驱动基因的干细胞及其用途 |
| GB2627085B (en) * | 2019-11-06 | 2024-11-13 | Univ Leland Stanford Junior | Methods and systems for analysing nucleic acid molecules |
| FR3105738B1 (fr) * | 2019-12-26 | 2024-01-05 | P M B | Dispositif d’irradiation collaboratif |
| CN112698037B (zh) * | 2021-03-25 | 2021-06-25 | 北京积水潭医院 | 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用 |
| CN116679065B (zh) * | 2023-07-31 | 2023-11-14 | 北京大学人民医院 | 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012500389A (ja) * | 2008-08-12 | 2012-01-05 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 多発性脊髄腫の診断、予後および治療のためのマイクロｒｎａに基づく組成物および方法 |
| AU2010319322A1 (en) * | 2009-11-13 | 2012-05-31 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| CN104126017A (zh) * | 2011-11-11 | 2014-10-29 | 米伦纽姆医药公司 | 对蛋白酶体抑制剂的反应的生物标记 |
| WO2014151117A1 (en) * | 2013-03-15 | 2014-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and use of circulating nucleic acid tumor markers |
| HK1222209A1 (zh) * | 2013-10-19 | 2017-06-23 | Trovagene, Inc. | 隨時間檢測疾病中的突變 |
-
2016
- 2016-12-02 AU AU2016363113A patent/AU2016363113A1/en not_active Abandoned
- 2016-12-02 CN CN201680070973.XA patent/CN108603232A/zh active Pending
- 2016-12-02 CA CA3007426A patent/CA3007426A1/en active Pending
- 2016-12-02 WO PCT/AU2016/051191 patent/WO2017091865A1/en not_active Ceased
- 2016-12-02 EP EP16869417.2A patent/EP3384050A4/en not_active Withdrawn
- 2016-12-02 KR KR1020187018220A patent/KR20180088690A/ko not_active Withdrawn
- 2016-12-02 JP JP2018548246A patent/JP2018537128A/ja active Pending
- 2016-12-02 US US15/776,770 patent/US20180282820A1/en not_active Abandoned
-
2021
- 2021-10-07 JP JP2021165655A patent/JP2022000059A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107881233A (zh) * | 2017-10-31 | 2018-04-06 | 天津协和华美医学诊断技术有限公司 | 一种检测骨髓瘤相关基因群的检测试剂盒 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017091865A1 (en) | 2017-06-08 |
| JP2018537128A (ja) | 2018-12-20 |
| EP3384050A1 (en) | 2018-10-10 |
| KR20180088690A (ko) | 2018-08-06 |
| EP3384050A4 (en) | 2019-07-31 |
| US20180282820A1 (en) | 2018-10-04 |
| JP2022000059A (ja) | 2022-01-04 |
| AU2016363113A1 (en) | 2018-06-07 |
| CN108603232A (zh) | 2018-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180282820A1 (en) | Monitoring treatment or progression of myeloma | |
| US12139763B2 (en) | Methods for subtyping of lung adenocarcinoma | |
| AU2020200128B2 (en) | Non-invasive determination of methylome of fetus or tumor from plasma | |
| US11111541B2 (en) | Diagnostic MiRNA markers for Parkinson's disease | |
| JP6513622B2 (ja) | 非侵襲的出生前診断に有用な母体試料由来の胎児核酸のメチル化に基づく富化のためのプロセスおよび組成物 | |
| US10457988B2 (en) | MiRNAs as diagnostic markers | |
| AU2021291586A1 (en) | Multimodal analysis of circulating tumor nucleic acid molecules | |
| US20250137066A1 (en) | Compostions and methods for diagnosing lung cancers using gene expression profiles | |
| US20170130269A1 (en) | Diagnosis of neuromyelitis optica vs. multiple sclerosis using mirna biomarkers | |
| WO2017112738A1 (en) | Methods for measuring microsatellite instability | |
| KR101828125B1 (ko) | 다발성 경화증에서의 진단 miRNA 프로파일 | |
| JP5865241B2 (ja) | 肉腫の予後分子署名およびその使用 | |
| US20260117306A1 (en) | Use of multi-nucleotide and structural variants for improved sensitivity and specificity of circulating tumor dna assays | |
| KR102085663B1 (ko) | Wrb 유전자의 메틸화 수준을 이용한 소혈관폐색증의 예측 또는 진단을 위한 정보제공방법 및 이를 위한 조성물 | |
| WO2017106365A1 (en) | Methods for measuring mutation load | |
| KR102816628B1 (ko) | 대사증후군 특이적 후성유전 메틸화 마커 및 이의 용도 | |
| Tsui et al. | Applications of circulating DNA analysis in personalized medicine | |
| JP2026505350A (ja) | 尿中の腎同種移植片拒絶反応遺伝子を同定するための方法およびそれらの測定を行うことの有用性 | |
| CN118139987A (zh) | 用于cfrna和cftna靶向ngs测序的组合物和方法 | |
| BRPI1006640A2 (pt) | métodos e reagentes para a detecção precoce de melanoma | |
| HK1207124B (zh) | 从血浆无创测定胎儿或肿瘤的甲基化组 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211202 |